Clinical Trials Logo
  1. Home
  2. Ductal Carcinoma In Situ
  3. NCT06133647
  4. Details
NCT06133647 Clinical Trial

Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health System

Ductal Carcinoma in Situ Clinical Trial

Official title:
Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health System

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT06133647
Other study ID # 015.MTP.2023.A
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 4, 2023
Est. completion date May 4, 2024

Study information
Verified date January 2024
Source Methodist Health System
Contact Colette N Ngo Ndjom, MS
Phone 214-947-1280
Email MHSIRB@mhd.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To determine the number of MBC cases as well as the demographics, characteristics, and outcomes of MBC patients at Methodist Health System (MHS).

Description:

Male breast cancer (MBC) is a rare disease without sufficient clinical data supporting the management and treatment. The treatment of MBC arises from data extrapolated from female breast cancer (FBC). MBC has higher mortality than FBC. Previous studies have suggested differences between MBC and FBC; however, treatments remain the same for both. Larger studies in MBC are needed to provide more clinical data to help guide treatment.

Recruitment information / eligibility
Status Recruiting
Enrollment 8
Est. completion date May 4, 2024
Est. primary completion date May 4, 2024
Accepts healthy volunteers
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - • = 18 years of age Patients diagnosed with ductal carcinoma in situ or invasive lobular carcinoma of the breast Exclusion Criteria: - 18 years of age - Prisoners - Pregnant or breastfeeding

Study Design

Related Conditions & MeSH terms

Intervention

Procedure:
• managing Male Breast Cancer Patients at Methodist Health System
To determine the number of MBC cases as well as the demographics, characteristics, and outcomes of MBC patients at Methodist Health System (MHS).

Locations
Country Name City State
United States Clinical Research Institute at Methodist Health System Dallas Texas
United States Clinical Research Institute at Methodist Health System Dallas Texas

Sponsors (1)
Lead Sponsor Collaborator
Methodist Health System

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Diagnosis Rates of patients with MBC and FBC complications of treatment 13 years
Primary Recurrence rates of Patients with MBC and FBC Recurrence rates of Patients with MBC and FBC 13 years
Primary Duration of remission in Patients with MBC and FBC Duration of remission in Patients with MBC and FBC 13 years
Primary The Overall Survival of patients with MBC and FBC after receiving treatment The Overall Survival of patients with MBC and FBC after receiving treatment 13 years
Primary Determine the complications of Treatment in patients with MBC and FBC Determine the complications of Treatment in patients with MBC and FBC 13 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02889458 - Hong Kong Breast Cancer Study
Completed NCT00757302 - Intraoperative Gamma Camera for Breast Cancer Surgery Phase 3
Recruiting NCT03216421 - Intraoperative Radiation Therapy (IORT) in DCIS N/A
Completed NCT03775213 - Acceptability of Active Monitoring (AM) as a Treatment Option for Ductal Carcinoma in Situ (DCIS) N/A
Active, not recruiting NCT00605982 - Breast MRI as a Preoperative Tool for DCIS N/A
Enrolling by invitation NCT04365114 - Patient Outcomes From Second Film-readers and Test Threshold Relaxation in Breast Screening
Completed NCT04248179 - The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery. Phase 4
Withdrawn NCT05032079 - Subzero and Scorpion Trial N/A
Recruiting NCT05218044 - Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ N/A
Active, not recruiting NCT01644669 - Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System® N/A
Completed NCT01815476 - The Prone Breast Radiation Therapy Trial N/A
Not yet recruiting NCT06033092 - Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion Phase 2
Terminated NCT02137252 - Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer Phase 2
Terminated NCT01060345 - A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ Phase 2
Recruiting NCT00669747 - Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS) Phase 2
Completed NCT00742222 - Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer Phase 4
Active, not recruiting NCT02909426 - The Mammography and Ultrasonography STudy for Breast Cancer Screening Effectiveness
Recruiting NCT02928978 - Ruxolitinib for Premalignant Breast Disease Phase 2
Completed NCT03375892 - The Use of Deep Inspiration Breath Hold and Prone Irradiation to Decrease Cardiac Radiation Exposure N/A
Withdrawn NCT03437915 - BrUOG 351: PRE-OPERATIVE APBI USING NIBB N/A